Overview

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients.

Status:
Terminated

Trial end date:
2021-03-25

Target enrollment:

Participant gender:

Summary

This is a Phase I/II clinical study to determine the maximum tolerated dose (MTD), and schedule, safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2811 monotherapy or with combination agent(s) in relapsed/refractory acute myeloid leukaemia (AML) patients or treatment-naïve AML patients not eligible for intensive induction therapy. In addition, the study will explore the potential clinical activity by assessing anti-tumour activity in patients. There are two parts to this study: Part A, dose escalation, and Part B, dose expansion.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Azacitidine
Pyrazole
Venetoclax